Qurient Co., Ltd. (KOSDAQ:115180)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,540
+210 (2.03%)
At close: Aug 5, 2025, 3:30 PM KST
2.03%
Market Cap393.96B
Revenue (ttm)8.99B
Net Income (ttm)-24.32B
Shares Out37.99M
EPS (ttm)-751.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,635
Average Volume73,175
Open10,260
Previous Close10,330
Day's Range10,260 - 10,600
52-Week Range3,200 - 13,080
Beta0.66
RSI43.68
Earnings DateAug 13, 2025

About Verve Therapeutics

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 31
Stock Exchange KOSDAQ
Ticker Symbol 115180
Full Company Profile

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.

Financial Statements

News

There is no news available yet.